Thiazolidinediones increase bladder cancer risk while SGLT2 inhibitors show potential protective effects in Type 2 Diabetes
Diabetes medications show different links to bladder cancer risk
This meta-analysis of 85 studies evaluated the association between various antidiabetic medications and bladder cancer risk in patients with…
New data shows that while some diabetes medications may increase bladder cancer risk, others might offer a protective effect.
SGLT2 inhibitors reduce risk of diabetic retinopathy progression (rr 0.77) and macular edema progression (rr 0.75)
SGLT2 inhibitors show promise in slowing diabetic eye disease
This meta-analysis of 1,785,409 patients with established diabetic retinopathy (DR) or diabetic macular edema (DME) found that SGLT2i therap…
A large analysis suggests SGLT2 inhibitors may slow the progression of vision-threatening complications in people with diabetes.
Glucagon-like peptide-1 receptor agonists associated with reduced Parkinson's disease risk in type 2 diabetes
New Data Suggests Specific Diabetes Medications May Lower Risk of Parkinson Disease
Researchers analyzed real-world data to evaluate the association between GLP-1RAs and Parkinson's disease risk in patients with type 2 diabe…
A large study shows that people with type 2 diabetes taking GLP-1 receptor agonists may have a lower risk of developing Parkinson disease.
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
GLP-1RA use shows sex-specific pancreatitis and hypotension risks in T2D second-line therapy study
Diabetes drugs work differently in women than men
A retrospective cohort study of 5.15 million adults with type 2 diabetes compared second-line therapies.
Diabetes drugs work differently for women than men, revealing distinct safety and effectiveness outcomes in a massive study of 5 million adu…